BACKGROUND AND PURPOSE: The corticobasal syndrome (CBS) is a clinical diagnosis that comprises a group of rare neurodegenerative diseases manifesting in movement disorder and cognitive impairment. While diagnosis is based upon clinical criteria, there have been a number of molecular imaging studies, albeit in rather small cohorts. Therefore, we investigated the pattern of cerebral glucose metabolism, as well as dopamine transporter (DAT) availability in a large and clinically well-defined cohort. METHODS: Thirty-four patients fulfilling either the Armstrong or the Boeve criteria were assessed with [18 F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and/or [123 I]-Ioflupane single-photon-emission-computed tomography (SPECT) for DAT availability. A small subset of patients had also undergone D2/3 receptor imaging. Imaging data were analyzed using both statistical parametric mapping and a volume-of-interest-based approach relative to data from healthy controls. RESULTS: Significant reductions of the cortical glucose metabolism were observed in the central region and the adjacent frontal and parietal association areas contralateral to the side with predominant motor symptoms. Reductions were also evident in the basal ganglia, notably in the putamen contralateral to the clinically affected side, and in the bilateral thalamus. DAT availability was reduced bilaterally, most distinctly on the side contralateral to the main motor symptoms. CONCLUSIONS: We replicated and refined earlier findings of impaired glucose metabolism and nigrostriatal degeneration in CBS, highlighting asymmetric cortical and subcortical hypometabolism, symmetrically reduced metabolism in the thalamus, and only a slightly asymmetric reduction in DAT, while D2/3 receptors seem to be mainly preserved. These results provide systematic evidence for the usefulness of FDG PET and dopaminergic SPECT imaging to characterize CBS.
BACKGROUND AND PURPOSE: The corticobasal syndrome (CBS) is a clinical diagnosis that comprises a group of rare neurodegenerative diseases manifesting in movement disorder and cognitive impairment. While diagnosis is based upon clinical criteria, there have been a number of molecular imaging studies, albeit in rather small cohorts. Therefore, we investigated the pattern of cerebral glucose metabolism, as well as dopamine transporter (DAT) availability in a large and clinically well-defined cohort. METHODS: Thirty-four patients fulfilling either the Armstrong or the Boeve criteria were assessed with [18 F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and/or [123 I]-Ioflupane single-photon-emission-computed tomography (SPECT) for DAT availability. A small subset of patients had also undergone D2/3 receptor imaging. Imaging data were analyzed using both statistical parametric mapping and a volume-of-interest-based approach relative to data from healthy controls. RESULTS: Significant reductions of the cortical glucose metabolism were observed in the central region and the adjacent frontal and parietal association areas contralateral to the side with predominant motor symptoms. Reductions were also evident in the basal ganglia, notably in the putamen contralateral to the clinically affected side, and in the bilateral thalamus. DAT availability was reduced bilaterally, most distinctly on the side contralateral to the main motor symptoms. CONCLUSIONS: We replicated and refined earlier findings of impaired glucose metabolism and nigrostriatal degeneration in CBS, highlighting asymmetric cortical and subcortical hypometabolism, symmetrically reduced metabolism in the thalamus, and only a slightly asymmetric reduction in DAT, while D2/3 receptors seem to be mainly preserved. These results provide systematic evidence for the usefulness of FDG PET and dopaminergic SPECT imaging to characterize CBS.
Authors: Neetu Soni; Manish Ora; Girish Bathla; Chandana Nagaraj; Laura L Boles Ponto; Michael M Graham; Jitender Saini; Yusuf Menda Journal: Neuroradiol J Date: 2021-03-05
Authors: Leonie Beyer; Johanna Meyer-Wilmes; Sonja Schönecker; Jonas Schnabel; Eva Brendel; Catharina Prix; Georg Nübling; Marcus Unterrainer; Nathalie L Albert; Oliver Pogarell; Robert Perneczky; Cihan Catak; Katharina Bürger; Peter Bartenstein; Kai Bötzel; Johannes Levin; Axel Rominger; Matthias Brendel Journal: Front Neurol Date: 2018-06-20 Impact factor: 4.003
Authors: Julia Schmitt; Carla Palleis; Julia Sauerbeck; Marcus Unterrainer; Stefanie Harris; Catharina Prix; Endy Weidinger; Sabrina Katzdobler; Olivia Wagemann; Adrian Danek; Leonie Beyer; Boris-Stephan Rauchmann; Axel Rominger; Mikael Simons; Peter Bartenstein; Robert Perneczky; Christian Haass; Johannes Levin; Günter U Höglinger; Matthias Brendel Journal: Front Aging Neurosci Date: 2021-05-13 Impact factor: 5.750